Giovannini M, Seitz J F
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Cancer. 1994 Jan 15;73(2):294-7. doi: 10.1002/1097-0142(19940115)73:2<294::aid-cncr2820730210>3.0.co;2-j.
Ultrasound-guided percutaneous alcohol injection (PAI) is used in the treatment of hepatocellular carcinoma. The aim of this study is to evaluate the results of treatment with PAI of liver metastases (LM) that measure fewer than 5 cm in diameter, where three or less lesions are present.
Between December 1987 and November 1992, 40 patients were treated for one or more liver tumors (n < or = 3). These 40 patients had a total of 55 lesions. There were 55 LM: 32 cases of colorectal origin, 9 cases of mammary origin, 5 cases with a carcinoid tumor, 4 with an undifferentiated tumor, 3 with cancer of the uterus, 1 with an epidermoid cancer of the esophagus, and 1 with a bronchogenic carcinoma. The tumor has been considered spherical and the total volume of alcohol used depends on the diameter of the tumor. The volume was calculated using the formula V = 4/3 pi [r + 0.5]3; this volume was injected during several sessions, not more than 10 ml per injection. The injections were performed once a week until the calculated volume was reached.
Of the 55 tumors treated, there was a complete necrosis in 31 cases (56.3%). The median survival of the 40 patients was 21 months, with a 3-year actuarial survival of 39%. Among patients with LM of colorectal origin, the median survival was increased when the total necrosis was obtained (38 months versus 21 months, P < 0.04).
PAI seems to be a therapeutic alterative when surgery is contraindicated or when LM are resistant to chemotherapy.
超声引导下经皮酒精注射(PAI)用于治疗肝细胞癌。本研究旨在评估PAI治疗直径小于5cm、病灶数为3个或更少的肝转移瘤(LM)的效果。
1987年12月至1992年11月期间,40例患者接受了一个或多个肝肿瘤(n≤3)的治疗。这40例患者共有55个病灶。其中有55个肝转移瘤:32例起源于结肠直肠,9例起源于乳腺,5例为类癌肿瘤,4例为未分化肿瘤,3例为子宫癌,1例为食管表皮样癌,1例为支气管癌。肿瘤被视为球形,所用酒精的总体积取决于肿瘤的直径。体积通过公式V = 4/3π[r + 0.5]³计算得出;该体积在多个疗程中注射,每次注射不超过10ml。每周进行一次注射,直至达到计算出的体积。
在接受治疗的55个肿瘤中,31例(56.3%)出现完全坏死。40例患者的中位生存期为21个月,3年精算生存率为39%。在结肠直肠源性肝转移瘤患者中,获得完全坏死后中位生存期延长(38个月对21个月,P<0.04)。
当手术禁忌或肝转移瘤对化疗耐药时,PAI似乎是一种治疗选择。